Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
OBJECTIVE
Management of malignant pleural mesothelioma (MPM) has been an important clinical issue regardless of the treatment modality employed. We aimed to investigate the efficacy of oxytetracycline (OT), Corynebacterium parvum (CP), and nitrogen mustard (NM) in the management of pleural effusion associated with MPM.


METHODS
One hundred and seventeen patients who had stage-2 MPM or over according to the Butchart staging system and unilateral or bilateral pleural effusion took part in the study. The patients received either OT (35 mg/kg), CP (7 mg), or NM (0.4 mg/kg) through a chest tube for pleurodesis. The association between several clinical parameters and patient survival was also investigated.


RESULTS
OT was applied to 59, CP to 29 and NM to 29 cases. A statistical analysis of the results obtained by these agents have demonstrated that OT (30 days, 81%; 90 days, 76.2%) and CP (30 days, 86.2%; 90 days, 79.3%) led to a significantly higher rate of successful pleurodesis as compared to NM (30 days, 48.2%; 90 days, 41.3%; p <0.05). Although the procedure was generally well tolerated by the patients, the NM-treated group experienced significantly more nausea-vomiting (46.1%) and hypotension (35.8%) compared to patients who received OT (nausea-vomiting and hypotension 4.3%; p < 0.001) and CP (nausea-vomiting and hypotension 5.1%; p < 0.001). Furthermore, we found that thrombocytosis, chest pain and weight loss were significantly associated with poor prognosis, whereas epithelial type had a positive effect on survival.


CONCLUSIONS
These results suggest that OT and CP may be used as effective sclerosing agents for pleurodesis in the control of pleural effusions associated with MPM, without major side effects.
Senyiğit
A
A
Department of Chest Diseases, Faculty of Medicine,University of Dicle, Diyarbakir, Turkey. Senyigit@dicle.edu.tr
Bayram
H
H
Babayiğit
C
C
Topçu
F
F
Balci
A E
AE
Satici
O
O
D000328:Adult; D000368:Aged; D001194:Asbestos / Q000009:adverse effects; D015505:Chest Tubes / Q000009:adverse effects; D004781:Environmental Exposure / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage*; D008654:Mesothelioma / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D010118:Oxytetracycline / Q000008:administration & dosage*; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018700:Pleurodesis / Q000379:methods; D011425:Propionibacterium acnes; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D013907:Thoracostomy; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology
D012597:Sclerosing Solutions; D001194:Asbestos; D008466:Mechlorethamine; D010118:Oxytetracycline